Reimagining Treatment
Across Multiple Diseases

CUMBERLAND® PHARMACEUTICALS

Corporate Presentation

3Q 2026

A BIOPHARMACEUTICAL COMPANY

Nasdaq CPIX

Corporate Overview

- Significant value creation opportunities
- Attractive, underserved markets
- Compelling Phase 2 data in DMD
- Defined path to NDA
- Established safety profile
- Worldwide commercial rights
- Strong balance sheet
- Expected near-term news flow

Safe Harbor Statement


This presentation contains forward-looking statements concerning our product development, our technology, our intellectual property, our financial condition and our plans for research and development programs that involve risks, uncertainties and assumptions. These statements are based on the current estimates and assumptions of the management of Cumberland Pharmaceuticals as of the date of this presentation and are subject to uncertainty and changes in circumstances. Given these uncertainties, you should not place undue reliance upon these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties, assumptions and other factors that may cause the actual results of Cumberland Pharmaceuticals to be materially different from those reflected in such forward-looking statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, those set forth under the headings "Risk factors" and "Management's discussion and analysis of financial condition and results of operations" in our Form 10-K and Form 10-Q Reports on file with the SEC. The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. All statements contained in this presentation are made only as of the date of this presentation. More information can be found at www.cumberlandpharma.com.



Nation's Health Care Capital

Cumberland is headquartered in Nashville, Tennessee which is home to the largest concentration of health care companies in the United States



A DEFINING MOMENT

A New Cumberland: Value Unlocked, Focused on Innovation

Strategic Transaction

CLOSED SUMMER 2026

Cumberland Pharmaceuticals

integrated its commercial products and organization with

Apotex Health

U.S. Branded Business

Apotex: Canada's largest pharmaceutical company, subsequently listed on the TSX

$100M+	75%	Retained
Received	Expenses Eliminated	Clinical Pipeline Our most valuable asset

Legacy Product Portfolio

Product Development:

Product Acquisition:

IV ACETADOTE®

CALDOLOR®

KRISTALOSE®

VIBATIV®

Vaprisol®

Sancuso®

Talicia®

Cumberland's Branded Medicines Joined the Apotex U.S. Portfolio

APOTEX
Canadian-Based
Global Health Company

Company Overview

Profile

Cumberland is an innovation-driven biopharmaceutical company developing new therapies to address significant unmet medical needs and improve patient outcomes

Refined Mission

Advancing new therapies that address significant unmet medical needs

Focus

Late-stage clinical development, led by ifetroban, building on our record of developing, registering and delivering differentiated medicines

Development Candidates

Ifetroban has the potential to make a significant impact in several diseases with major unmet medical needs

Dyscorban® *(Duchenne muscular dystrophy)*

Vasculan® *(Systemic sclerosis)*

Fibroban® *(Idiopathic Pulmonary Fibrosis)*

Ifetroban *(Cancer metastasis prevention)*



Ifetroban Overview

- Cumberland's first **new chemical entity**
- A **potent, selective** antagonist of thromboxane receptor
- Discovered and initially developed by Bristol-Myers Squibb
- **Safety well-established** in 30 clinical studies with **over 1,400 subjects**
- Collaborating with **Vanderbilt Health** and other academic centers

Development Pipeline



Oral Ifetroban

- **Dyscorban®** ***(Duchenne muscular dystrophy cardiomyopathy)***
- **Vasculan®** ***(Systemic sclerosis cardiomyopathy)***
- **Fibroban®** ***(Idiopathic Pulmonary Fibrosis)***
- **Ifetroban** ***(Cancer metastasis prevention)***

Duchenne Muscular Dystrophy (DMD)


- **A rare, fatal, neuromuscular disease** with the progressive loss of muscle resulting in deterioration of the skeleton, heart and lungs
- Cumberland is investigating ifetroban for the treatment of **cardiomyopathy** that is associated with DMD
- **Preclinical data** demonstrates ifetroban could prevent cardiac fibrosis and improve cardiac function – published **Journal American Heart Association**
- The **FDA** has awarded over $1 million in **Orphan Drug Grant** funding
- **Orphan Drug** and **Rare Pediatric Disease** Designations approved
- **Phase 2 study** completed with **breakthrough results** announced
- **Fast Track Designation** and **rolling submission** of NDA also granted

Systemic Sclerosis (SSc)

- Debilitating, **chronic autoimmune disease** causing thickening of the skin and fibrosis of internal organs
- **Highest death rate** of any rheumatic condition
- Average **survival** is approximately **11 years** from diagnosis
- **Women** more commonly affected; also occurs in **children**
- No FDA approved treatment for this **unmet medical need**
- **Phase 2a study** enrollment completed
- **Top line study results** reported; well tolerated

Idiopathic Pulmonary Fibrosis (IPF)

- **Progressive Fibrosing Interstitial Lung Diseases** are a group of disorders that cause irreversible scarring (fibrosis) of lung tissue leading to lung function decline & early mortality
- Idiopathic **Pulmonary Fibrosis** (IPF) is the most common form of PF-ILDs
- **Orphan disease**
- IND cleared and **Phase 2 study** is well underway



Cancer Metastasis Prevention

- **Positive Results** from Phase 2a Clinical Trial
- Study met its primary endpoint demonstrating **safety and tolerability** of ifetroban in patients with high-risk solid tumors
- Trial revealed promising efficacy signals with **fewer deaths due to metastasis** in the ifetroban arm, than in the placebo arm (p=0.037)
- Results support development of ifetroban as a **candidate for metastasis prevention**
- **Follow on study** being designed



CET
Cumberland *Emerging* Technologies

CET®
Cumberland *Emerging* Technologies

- **Joint initiative** to build **long term pipeline**
- Collaborating with **Academic Research** Partners
- Building **portfolio** of innovative **biopharmaceutical candidates**
- Supporting product development through **grant initiatives**
- Managing Nashville's **Life Science Center**
- Houses **Cumberland's formulation** and **testing laboratories**

Income Statement

($ IN MILLIONS)	Q3 2026
Net Revenues	**$ 2**
Cost of Products Sold	1
Gross Profit	1
Research & Development	2
General Administrative	7
Interest Income	1
Gain on Strategic Transaction	81
Net Income	**$ 70**

Summary Balance Sheet

($ in millions)	**September 30, 2026**
Cash and Securities	$81
Total Assets	**114**
Total Liabilities	42
Total Equity	72
Total Liabilities and Equity	**$114**

Cumberland Moving Forward

- Significant value creation opportunities
- Compelling clinical trial results to date in DMD
- Established safety profile
- Ownership of worldwide commercial rights
- Solid financial position
- Expected near-term news flow



CUMBERLAND®
PHARMACEUTICALS

Nasdaq CPIX